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High-voltage device therapy is one of cardiology’s great
success stories of the past 20 years. Patients known to be at
risk of sudden deathdprincipally those with left ventricular
systolic dysfunctiondcan be identiﬁed in advance of their
arrhythmic events and prophylactic implantable cardioverter-
deﬁbrillator (ICD) therapy initiated. When the patient has
disordered intraventricular conduction, addition of cardiac
resynchronization therapy (CRT) has a further beneﬁcial,
albeit smaller, effect on mortality in addition to the desirable
reduction in heart failure symptoms and heart failure hospi-
talizations that CRT brings. Although the results of major
prospective randomized trials of transvenous ICD and CRT
therapy have all been consistent, implantation of high-voltage
devices in indicated patients is declining.See page 2406Prophylactic high-voltage device implantation began in
1996 with the publication of the ﬁrst primary prevention trial,
MADIT (Multicenter Automatic Deﬁbrillator Implantation
Trial) (1), and volume grew up to about 2005 (2). The early
CRT trials (COMPANION [Comparison of Medical
Therapy, Pacing, and Deﬁbrillation in Heart Failure] [3]
and MIRACLE [Multicenter InSync Randomized Clinical
Evaluation] [4]) and the subsequent introduction of the idea*Editorials published in the Journal of the American College of Cardiology reﬂect the
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CRT [5] and REVERSE [Resynchronization Reverses
Remodeling in Systolic Left Ventricular Dysfunction] [6])
bolstered the growth of high-voltage device implantation.
Since then, however, implantation rates have been declining
such that current rates are down by about one-quarter
compared with their peak period ( Jeffries Group Inc.,
unpublished data, 2013) (CitiGroup Investments, unpub-
lished data, March 23, 2011).
Why are high-voltage device implantation rates so low?
There are many possible reasons. It may be that the number
of appropriate patients is in fact smaller than anticipated
despite a larger pool of patients meeting indications. Recent
technological problems may inﬂuence physicians to shy away
from referring indicated patients. In addition, convincing
referring physicians of the clear mortality beneﬁt seems to be
an ongoing challenge.
This last point is addressed in the current article by
Finegold et al. (7) in this issue of the Journal. The authors
reviewed mortality beneﬁt from CRT in 7 major trials
comparing biventricular pacing versus no biventricular
pacing. They used the measurement of life span gained,
which has the advantage of providing a clinical context in
which to relate clinical trial results to individual patients.
Over 24 months of follow-up (the typical length of
a prospective randomized trial), they observed that life span
gained grew at a greater rate over time. The observed life
span gain at 24 months was >4 times greater than that at 12
months. Although it is widely accepted that CRT positively
affects mortality, the authors eloquently demonstrate the
durability of the beneﬁt.
Due to the overwhelming cost, clinical trials are designed
to last as long as necessary to prove or disprove beneﬁt. In the
case of CRT trials, this is approximately 2 years. However,
the life of a CRT device is about 5 years, and many patients
live long enough to receive >1 device. The authors (7)
extrapolated the hazard ratios over the life of a device (i.e.,
5 years), thus enabling them to estimate the life span gained.
Although clearly relying on assumptions, this is a practical
way of looking at longer-term results without prolonging
expensive clinical trials. When the authors reviewed the
life span gained for the compiled trial data at 1, 2, 3, and
5 years after device implantation, it grew over time, and the
number-needed-to-treat (NNT) decreased. In fact, in
COMPANION (3), the NNT was 101.8 at 1 year and
dramatically dropped to 7.4 at 3 years. In CARE-HF
(CArdiac REsynchronization Heart Failure), the NNT was
75.8 and 6.0 at 1 and 3 years, respectively; in RAFT
(Resynchronization-deﬁbrillator Ambulatory Heat failure),
the NNT dropped from 91.3 at 1 year to 4.8 at 5 years.
Even more interesting were the ﬁndings of Finegold et al.
(7) when extrapolated to 15 and 20 years. At 5 and 10 years,
there was greater beneﬁt (more life span gained) in the
higher-risk patients. However, lower-risk patients live lon-
ger (they have less nonsudden cardiac and noncardiac
mortality), and at 15 and 20 years, they gained more beneﬁt
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These ﬁndings have a direct impact on clinical practice. It is
easy for us as clinicians to evaluate our New York Heart
Association functional class III and IV patients and feel
a need to do everything we can to prolong their lives as fast
as possible. We may not see the same urgency in treating our
patients who are better compensated, especially with device
therapy. However, the authors have demonstrated that over
time, these patients actually receive more beneﬁt from CRT.
This concept of durability of beneﬁt is not unique to
CRT, and we believe it is evident in the non-CRT ICD
trials as well. In MADIT II, the beneﬁt of ICD therapy was
not seen until 18 months (8). The 8-year follow-up data
showed that the absolute risk reduction was 13% and that
the NNT was 8 compared with 17 at 2 years (9). These
ﬁndings suggest that clinical beneﬁt extends at least
throughout the life span of the device. During the trial phase
of MADIT II, two-thirds of the patients did not receive
appropriate ICD therapy. However, this relatively large
group of low-risk patients derived beneﬁt over the longer-
term follow-up.
In a substudy of SCD-HeFT (Sudden Cardiac Death in
Heart Failure Trial), Levy et al. (10) divided the subjects
into risk quintiles. Implantation of an ICD reduced the
relative risk of sudden cardiac death by 88% in the lowest-
risk group versus a 24% reduction in the highest-risk
group. The mortality reduction was 54% in the lowest-risk
group compared with no mortality beneﬁt in the highest-
risk group. They then looked at life span gained and found
that the lowest-risk group gained approximately 6 years but
required multiple ICDs (about 3 over their predicted life
span). This is markedly longer than the 0.2 life-year gained
for the highest-risk patients.
There is further evidence regarding the nonuniformity of
beneﬁt of ICD therapy in the MADIT II data. Goldenberg
et al. (11) looked at their own clinical risk score to determine
who beneﬁts the most from primary prevention ICD therapy.
They chose several clinical risk factors, including New York
Heart Association functional class >II, age >70 years, blood
urea nitrogen level >26 mg/dl, QRS duration >0.12 s, and
atrial ﬁbrillation. They also identiﬁed a group of very-high-
risk patients with a blood urea nitrogen level >50 mg/dl
and/or serum creatinine level >2.5 mg/dl. Patients with at
least 1 risk factor had a 49% reduction in mortality, whereas
patients with no risk factors or who were deemed very high
risk had no beneﬁt (hazard ratio: 0.96 and 1.00, respectively).
In conclusion, it seems intuitively obvious that the sickest
patients will derive the most life span beneﬁt from prophy-
lactic high-voltage device implantation. But deﬁbrillators,
unlike other therapies commonly used in patients with heartfailure, have a beneﬁt that continues long after the device is
implanted. It is only by assessing this over a period of many
years and several devices that the full impact of therapy
will become apparent. The current article (9) and more
contemporary analyses of prophylactic ICD trials in different
groups of patients indicate that it is the lower-risk patients
who derive the most life span gain from these therapies. The
implication of this ﬁnding is that guideline-appropriate
patients should receive implants at an earlier stage in their
course than is currently common. The mortality beneﬁt will
take time to become apparent, but it is real and is of impor-
tance to individual patients.
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